BioTime Subsidiary OrthoCyte Corporation Announces the Appointment of Francois Binette as Vice President

  BioTime Subsidiary OrthoCyte Corporation Announces the Appointment of
  Francois Binette as Vice President

  Adds senior executive with significant experience in developing cell-based
                             orthopedic products

Business Wire

ALAMEDA, Calif. -- November 01, 2012

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OrthoCyte Corporation today
announced the appointment of Francois Binette, PhD, as OrthoCyte’s Vice
President of Research and Business Development. Dr. Binette’s primary focus
will be to develop and partner near- and long-term product opportunities in
regenerative medicine with an emphasis on orthopedic diseases and injuries.
OrthoCyte is a wholly owned subsidiary of BioTime, Inc. that develops cellular
therapeutics for orthopedic repair, diseases, and injuries.

“I am impressed by the robust nature of the novel and diverse progenitors of
skeletal tissues that BioTime has isolated using its ACTCellerate^TM
technology,” said Dr. Binette. “The ability to generate scalable and precisely
identified types of cartilage, bone, and tendon, combined with the HyStem^®
technology for tissue engineering, gives us a remarkable platform for
manufacturing an array of novel products to address some of the largest and
fastest growing needs in the orthopedic space. I look forward to building on
the science and technology developed at OrthoCyte to aggressively develop the
company’s product pipeline and pursue partnering opportunities.”

“Francois brings tremendous expertise in regenerative medicine, cell therapy,
biologics, biomaterials, and combination medical devices. He also has
significant business experience in partnering and collaboration with both
start-up and large life science companies,” said Michael D. West, PhD,
BioTime’s Chief Executive Officer. “We welcome Francois to the OrthoCyte team
and look forward to working together with him in developing commercial product
opportunities for the orthopedic repair market.”

Dr. Binette most recently was the founder of Rediens Inc., a Bay Area start-up
company focused on chronic back pain therapies. Prior to establishing Rediens,
he wasDirector of BiologicsR&D for the Spinal & Biologics business unit of
Medtronic, Inc., and he also served in a variety of positions with Johnson &
Johnson, where he focused on regenerative medicine therapies for various
orthopedic indications, including cartilage injuries and back pain. Dr.
Binette began his corporate career at Genzyme Tissue Repair, where he helped
pioneer Carticel, the first FDA Biologic License Application-approved cell
therapy product. Dr. Binette received his PhD in Biochemistry at Laval
University in Québec and was a postdoctoral research fellow at the LaJolla
Cancer Research Foundation of the Sanford-Burnham Medical Research Institute
and at MGH/Harvard Medical School. He is currently a fellow with the
International Cartilage Repair Society.

About OrthoCyte Corporation

OrthoCyte Corporation (OrthoCyte),, a subsidiary of BioTime,
Inc., is a biotechnology company developing cell-based therapies for
orthopedic disease. The company's lead product is OTX-CP07, monoclonal human
embryonic progenitor cell lines for the repair of osteoarthritis. In addition,
OrthoCyte has proprietary human embryonic stem cell-derived progenitors to
skeletal muscle, tendon, and bone, all of which are in the preclinical phase
of development.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company
focused on regenerative medicine and blood plasma volume expanders. Its broad
platform of stem cell technologies is enhanced through subsidiaries focused on
specific fields of application. BioTime develops and markets research products
in the fields of stem cells and regenerative medicine, including a wide array
of proprietary ACTCellerate™ cell lines, HyStem^® hydrogels, culture media,
and differentiation kits. BioTime is developing Renevia™ (formerly known as
HyStem^®-Rx), a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. BioTime's therapeutic
product development strategy is pursued through subsidiaries that focus on
specific organ systems and related diseases for which there is a high unmet
medical need. BioTime's majority-owned subsidiary Cell Cure Neurosciences Ltd.
is developing therapeutic products derived from stem cells for the treatment
of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte
Corporation is developing therapeutic applications of stem cells to treat
orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation,
focuses on the diagnostic and therapeutic applications of stem cell technology
in cancer, including the diagnostic product PanC-Dx™ currently being developed
for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent stem cell
technology to reverse the developmental aging of human cells to treat
cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences,
Inc. markets GeneCards^®, the leading human gene database, and is developing
an integrated database suite to complement GeneCards^® that will also include
the LifeMap™ database of embryonic development, stem cell research and
regenerative medicine, and MalaCards, the human disease database. LifeMap will
also market BioTime research products. BioTime's lead product, Hextend^®, is a
blood plasma volume expander manufactured and distributed in the U.S. by
Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive
licensing agreements. Additional information about BioTime can be found on the
web at

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future
growth in research, technology, clinical development, and potential
opportunities for BioTime and its subsidiaries, along with other statements
about the future expectations, beliefs, goals, plans, or prospects expressed
by management constitute forward-looking statements. Any statements that are
not historical fact (including, but not limited to statements that contain
words such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or commercialization of
potential products, uncertainty in the ability to identify and complete
potential acquisitions, the ability to realize anticipated benefits of and
achieve expected financial performance following completed acquisitions, the
results of clinical trials or regulatory approvals, need and ability to obtain
future capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with the
many uncertainties that affect the business of BioTime and its subsidiaries,
particularly those mentioned in the cautionary statements found in BioTime's
Securities and Exchange Commission filings. BioTime disclaims any intent or
obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list:


BioTime, Inc.
Peter Garcia, 510-521-3390, ext 367
Chief Financial Officer
Judith Segall, 510-521-3390, ext 301
Press spacebar to pause and continue. Press esc to stop.